Iteos Therapeutics Inc
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lym… Read more
Iteos Therapeutics Inc (ITOS) - Total Assets
Latest total assets as of June 2025: $623.08 Million USD
Based on the latest financial reports, Iteos Therapeutics Inc (ITOS) holds total assets worth $623.08 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Iteos Therapeutics Inc - Total Assets Trend (2018–2024)
This chart illustrates how Iteos Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Iteos Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Iteos Therapeutics Inc's total assets of $623.08 Million consist of 74.2% current assets and 25.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.7% |
| Accounts Receivable | $3.69 Million | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Iteos Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Iteos Therapeutics Inc's current assets represent 74.2% of total assets in 2024, a decrease from 86.4% in 2018.
- Cash Position: Cash and equivalents constituted 20.7% of total assets in 2024, down from 80.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Iteos Therapeutics Inc Competitors by Total Assets
Key competitors of Iteos Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Iteos Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Iteos Therapeutics Inc generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Iteos Therapeutics Inc is currently not profitable relative to its asset base.
Iteos Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.53 | 18.08 | 33.49 |
| Quick Ratio | 7.53 | 18.08 | 33.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $458.72 Million | $ 591.94 Million | $ 335.41 Million |
Iteos Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Iteos Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.91 |
| Latest Market Cap to Assets Ratio | 0.49 |
| Asset Growth Rate (YoY) | 2.9% |
| Total Assets | $686.98 Million |
| Market Capitalization | $339.96 Million USD |
Valuation Analysis
Below Book Valuation: The market values Iteos Therapeutics Inc's assets below their book value (0.49 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Iteos Therapeutics Inc's assets grew by 2.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Iteos Therapeutics Inc (2018–2024)
The table below shows the annual total assets of Iteos Therapeutics Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $686.98 Million | +2.90% |
| 2023-12-31 | $667.59 Million | -11.58% |
| 2022-12-31 | $754.99 Million | -14.66% |
| 2021-12-31 | $884.71 Million | +156.77% |
| 2020-12-31 | $344.56 Million | +1020.73% |
| 2019-12-31 | $30.74 Million | +12.24% |
| 2018-12-31 | $27.39 Million | -- |